CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
At the AACC show 2015
Nuclea Biotechnologies will begin offering more than 50 research-use-only mass spectrometry–based biomarker tests as part of its laboratory services. The tests detect and quantify protein biomarkers in human serum or plasma and are available to pharmaceutical companies for clinical trials, to researchers, and as companion diagnostics.
“With the advent of monoclonal antibody-based and other protein-based drugs, it has become crucial for researchers to access precise companion diagnostic assays for targeted proteins. Mass spectrometry–based tests can selectively detect and quantify protein drug targets at the sequence level,” Mary F. Lopez, PhD, chief operating officer and vice president of proteomics discovery at Nuclea, said in a statement.
Nuclea’s CLIA-certified laboratory, in Pittsfield, Mass., offers an array of validated and reimbursable immunohistochemistry and ELISA tests for cancer-associated protein in tissue and blood. Nuclea will launch a second high-complexity CLIA lab in its Cambridge, Mass., facility later this year. In addition to IHC and ELISA tests, this lab will offer mass spectrometry multiplexed assays for serum or plasma proteins associated with diabetes, metabolic syndrome, and obesity.
Nuclea Biotechnologies, 413-749-4705